11.18
0.01 (0.13%)
Penutupan Terdahulu | 11.17 |
Buka | 11.13 |
Jumlah Dagangan | 1,592,166 |
Purata Dagangan (3B) | 5,287,120 |
Modal Pasaran | 998,867,648 |
Harga / Jualan (P/S) | 16.14 |
Harga / Buku (P/B) | 2.11 |
Julat 52 Minggu | |
Tarikh Pendapatan | 14 Aug 2025 |
Margin Operasi (TTM) | -111.10% |
EPS Cair (TTM) | -2.11 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 479.00% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 14.50% |
Nisbah Semasa (MRQ) | 9.84 |
Aliran Tunai Operasi (OCF TTM) | -142.46 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.11 M |
Pulangan Atas Aset (ROA TTM) | -19.35% |
Pulangan Atas Ekuiti (ROE TTM) | -34.26% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Verve Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -0.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -5.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 4.0 |
Purata | 0.25 |
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 5.10% |
% Dimiliki oleh Institusi | 94.63% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 24.00 (Guggenheim, 114.59%) | Beli |
Median | 13.25 (18.47%) | |
Rendah | 11.00 (Jefferies, -1.65%) | Pegang |
Purata | 14.50 (29.65%) | |
Jumlah | 1 Beli, 5 Pegang | |
Harga Purata @ Panggilan | 10.15 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
BMO Capital | 27 Jun 2025 | 13.50 (20.71%) | Pegang | 11.18 |
HC Wainwright & Co. | 18 Jun 2025 | 13.50 (20.71%) | Pegang | 11.12 |
14 Apr 2025 | 25.00 (123.53%) | Beli | 4.12 | |
Jefferies | 18 Jun 2025 | 11.00 (-1.65%) | Pegang | 11.12 |
LifeSci Capital | 18 Jun 2025 | 12.00 (7.30%) | Pegang | 11.12 |
Canaccord Genuity | 17 Jun 2025 | 13.00 (16.24%) | Pegang | 11.38 |
15 Apr 2025 | 39.00 (248.71%) | Beli | 4.97 | |
Guggenheim | 15 Apr 2025 | 24.00 (114.59%) | Beli | 4.97 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |